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INTRODUCTION 
CANDIDIOSIS 
Candida albicans (C. albicans) is part of the normal microbial flora in human beings and domestic animals, and 
is associated with the mucous surfaces of the oral cavity, gastrointestinal tract and vagina. Immune dysfunction 
can allow C. albicans to switch from a commensal to a pathogenic organism capable of infecting a variety of 
tissues and causing a possibly fatal systemic disease (Traynor and Huffnagle, 2001). Mucosal infection is the most 
usual form of the disease but cutaneous lesions are seen on occasion (Lehmann, 1985). 
In cattle, as a consequence of the abundant use, and occasional abuse, of antibiotics in the treatment of mastitis, 
there is a selection of flora, mainly members of the genus Candida, that are new etiological agents of these 
processes, which are initially difficult to diagnose because their presence is not expected. Candidiasis in birds is 
related to malnutrition and stress, generally produced by the same strains that are found naturally on the food plants 
of these animals. Arthritis caused by yeasts in horses is relatively frequent as a consequence of contamination of 
wounds or after surgical treatment. In pigs, candidiasis usually takes the form of digestive alterations in young 
animals, and is usually related to problems that predispose to the disease, like treatment with antibiotics (Garcia 
and Blanco, 2000). C. albicans is a common causative agent of stomatitis in the dog (Jadhav and Pal, 2006). 
Although fungi need pre deponent factors to produce the disease, it is known that saprophytic colonization of the 
mucous membrane by C. albicans does not need the host to be immune compromised, since it is detected in 
immune competent individuals (Garcia and Blanco, 2000). 
Etiology  
Candidosis is the most common fungal infection of the oral cavity and is caused by an overgrowth of commensal 
Candida species. Candida albicans (C. albicans) is the most commonly isolated species in both health and disease. 
Less common species include C. glabrata, C. tropicalis, C. guilliermondii, C. krusei, C. parapsilosis, and C. kefyr, 
and more recently, C. dubliniensis (Neville et al., 2002). 
Host risk factors 
Endocrine disorders 
Diabetes mellitus (DM) may increase susceptibility to development of candidal infections owing to immune 
system aberrations such as impaired opsonization and decreased chemotactic activity of neutrophils and monocytes 
(van Burik &Magee, 2001). Candida-associated lesions including denture stomatitis, median rhomboid glossitis, 
and angular cheilitis have been reported to be more prevalent in patients with DM (Guggenheimer et al., 2000). 
The individuals with DM are more prone to candidal infections, particularly when host resistance is modified due 
to local factors such as smoking and denture wearing (Dorocka-Bobkowska et al., 1996).Patients with poorly 
controlled DM may exhibit reduced salivary flow rates, reduced salivary pH, increased salivary glucose levels -
factors known to facilitate oral candida growth and colonization (Bell et al., 1999). 
Nutritional factors 
Several nutritional deficiencies may result in a diminished host defense and loss of epithelial integrity, which may 
facilitate subsequent fungal invasion and infection (Sherman et al., 2002). 
Iron deficiency anemia has been proposed as an important factor in the etiology of oral candidosis (Paillaud 
et al., 2004). Decreased lymphocyte response to Candida antigens in some iron-deficient subjects was associated 
with an increased frequency of C. albicans in the oral cavity, suggesting that iron deficiency may predispose to 
oral candidosis by depressing cell-mediated immunity (Sweeney et al., 1994). Deficiencies of vitamin B12 and 
folic acid may also predispose to oral candidosis (Davenport et al., 2001). 
Immune defects, immunosuppression 
Oral candidiasis is a common manifestation in a variety of immune deficiencies. Both humoral and cell-mediated 
immune systems participate in the prevention and elimination of candidosis (Farah et al., 2010). Reduced or 
defective immune function increases susceptibility to such infections. In HIV infection, the immunodeficiency 
affecting T-helper lymphocytes makes the infected patients more predisposed to secondary infections, notably 
opportunistic candidal infections (Farah et al., 2000). 
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High-carbohydrate diet 
High-carbohydrate intake has been assumed to predispose to oral candidosis. This is supported by in vitro studies 
showing that the growth of Candida in saliva is enhanced by glucose despite the presence of a nutrient competing 
bacterial salivary flora (Basson, 2000). Furthermore, the adhesive properties of C. albicans to oral epithelial cells 
and to acrylic surfaces are augmented by dietary carbohydrates.  In studies investigating the effects of dietary 
sugars on candidal adhesion and biofilm formation, glucose was shown to be the most effective followed by 
galactose and sucrose (Jin et al., 2004). 
Pathogenesis 
Virulence factors 
C. albicans has several known virulence factors contributing to its pathogenicity that include adherence to 
epithelial and endothelial cells, proteinase production (Ross et al., 1990), hypha and pseudohypha formation (Odds 
et al., 1988), phenotypic switching , phospholipase production (Ibrahim et al., 1995 ), and antigenic modulation as 
a result of pseudohypha formation (DeBernardis et al., 1994). If C. glabrata is low in virulence, the lack of hypha 
formation may be a contributing factor. Indeed, hypha formation is a recognized means of increased adherence 
and tissue invasion by C. albicans as well as a means of increasing proteolytic enzyme elaboration and antigen 
modulation (Odds, 1988). 
Adherence is an extremely important virulence factor, although the actual adherence property may be 
compounded by other virulence properties. For example, cell surface hydrophobicity (CSH), which is affected by 
environmental factors, can affect specific adherence based upon interaction of adhesin receptors. In a study with 
limited numbers of C. glabrata isolates tested, C. glabrata was shown to have comparable CSH to C. albicans 
(Klotz et al., 1988). 
Extracellular membrane-damaging phopholipases are considered virulence factors for C. albicans (Ibrahim 
et al., 1995). Although these enzymes have not been studied extensively, phospholipase A and B and 
lysophospholipase-transacylase are produced by virulent but not avirulent (commensal) strains of C. albicans. 
These phospholipase-producing strains also adhered most strongly to epithelial cells. Furthermore, the production 
of these phospholipases by clinical isolates correlated with pathogenicity and was predictive of mortality in animal 
models (Ibrahim et al., 1995).  Another virulence factor of C. albicans is specific phenotypic instability, which 
allows strains to switch colony phenotype without affecting the identifiable genotype; this is termed “phenotypic 
switching” (Soll, 1988 & 1992). 
Host defenses 
Clinically, this is supported by the fact that neutropenic patients are particularly susceptible to systemic C. albicans 
infections. In addition, it has been shown in an animal model that T cells may be of some significance against 
systemic C. albicans infections. Specifically, studies in mice have shown that a Th1-type response characterized 
by the cytokines interleukin-2 (IL-2), gamma interferon, and IL-12 is associated with protection against systemic 
infection whereas Th2-type responses characterized by the cytokines IL-4, IL-5, and IL-10 and antibody 
production (immunoglobulin A [IgA] and IgE) is associated with susceptibility to systemic infection (Romani et 
al., 1996). T cells and cell-mediated immunity (CMI), on the other hand, form the predominant host defense 
mechanism against mucosal C. albicans infection. This comes from both clinical observations (a high incidence 
of mucosal candidiasis in patients with reduced CMI) and clinical and experimental studies showing the critical 
role of T cells in protection against C. albicans mucosal infections (i.e., chronic mucocutaneous candidiasis and 
gastrointestinal candidiasis) (Bennett,1990). 
Preventive measures 
Any nutritional deficiency states (iron, folate and vitamin B12), diabetes mellitus, and any immune deficiencies 
should be excluded (Farah et al., 2010; Williams et al., 2011; McCollough & Salvage, 2005). Any pharmacologic 
agents that may contribute should be identified, and if practical, substituted for an alternative drug. Use of 
corticosteroid inhalers for asthma should be coupled with rinsing the mouth with water after each use (Williams 
et al., 2011). 
 
ASPERGILLOSIS 
Aspergillosis is the group of diseases caused by Aspergillus. The most common subtype among paranasal sinus 
infections associated with aspergillosis is Aspergillus fumigatus (A. fumigatus). In humans, the major forms of 
disease are; Allergic bronchus pulmonary aspergillosis, which affects patients with respiratory diseases such as 
asthma, cystic fibrosis, and sinusitis, Acute invasive aspergillosis, a form that grows into surrounding tissue, more 
common in those with weakened immune systems such as AIDS or chemotherapy patients, Disseminated invasive 
aspergillosis, an infection spread widely through the body, Aspergilloma, a "fungus ball" that can form within 
cavities such as the lung (Bozkurt et al., 2008). 
In humans, the lungs are the most common location of Aspergillus infections but in domestic animals, the 
situation is different and varies between species. For example, in cows, the fore stomachs, especially the omasum, 
are mostly affected, from which the infection may spread to other organs, including the placenta (Garcia et al., 
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2001a). A few cases of pulmonary involvement and later dissemination have been reported in dogs (Clercx et al., 
1996). Aspergillosis of the air passages is also frequently reported in birds, and certain species of Aspergillus have 
been known to infect insects (Geiser, 2009). 
Etiology 
Aspergillus was first described in 1729 and receives its name due to its resemblance to an aspergillum used to 
sprinkle holy water. A member of the family Trichocomaceae, Aspergillus species are closely related to another 
mold, Penicillium. However, identification of the causative organism responsible for most infections is usually not 
difficult, with four species responsible for the majority of illnesses. A. fumigatus is responsible for more than 90% 
of invasive disease in some reviews, with Aspergillus flavus (A. flavus), Aspergillus terreus (A. terreus), and 
Aspergillus niger (A. niger) responsible for the majority of remaining invasive aspergillosis cases (Patterson et al., 
2000). 
Host risk factors 
Risk factors for invasive aspergillosis may be associated with the changes in macrophage and neutrophil function, 
which may explain why infection mainly affects bone marrow and solid organ transplant recipients, Intensive Care 
Unit (ICU) patients, post-operative patients, those with chronic pulmonary diseases, patients with AIDS and 
patients on immune modulating drugs (TNF-α inhibitors), neutropenic patients, or those who have received 
corticosteroid treatment. Other risk group is patients with chronic granulomatous disease, drug user, patients with 
sarcoidosis, severe burn patients and alcoholics (Ascioglu et al., 2002). Aspergillus can also develop when no risk 
factors are present. Thus, cases have been explained of community-acquired pneumonia due to Aspergillus in 
apparently immune competent patients (Franquet et al., 2001) but it is likely that the patients had some undetected 
defect in macrophage and neutrophil function that allowed invasive infection to develop. 
Malnutrition, vitamin deficiencies (especially vitamin A), long term antibiotic use, age  (young or old) also 
contributes to the presentation of the disease, as well as trauma,  dusty environments, lead poisoning and irritants 
of the airways like smoke of cigarette  or ammonia (Washburn et al., 1990). 
Pathogenesis 
Virulence factors 
Aspergilli produce catalase, an enzyme that breaks down hydrogen peroxide (H2O2) to water and oxygen. The 
strong association of aspergillosis with chronic granulomatous disease (CGD) (Cohen et al., 1981) provides 
indirect evidence that catalase is a virulence factor. A. fumigatus produces gliotoxin, a metabolite in the 
epipolythiodioxopiperazine family with a broad range of immunosuppressive properties. Gliotoxin inhibits 
macrophage phagocytosis (Eichner et al., 1986), as well as T-cell activation and proliferation. It induces DNA 
fragmentation and programmed cell death (apoptosis) in macrophages by mechanisms apparently distinct from its 
antiphagocytic properties (Waring, 1990). It is not known whether clinically significant amounts of gliotoxin are 
produced in human disease. In a case report, concentrations of gliotoxin approximately 100 times greater than that 
needed for in vitro effects were found in a bovine udder infected with A.fumigatus (Bauer et al., 1989). 
In addition to gliotoxin, A. fumigatus produces an 18-kDa cytotoxin that acts by cleaving a phosphodiester bond 
of the 28S rRNA of eukaryotic ribosomes (Smith et al., 1993). 
Host defense 
Antigen release evokes production of IgE, IgG and IgA antibody against the A.fumigatus and intense production 
of nonspecific total IgE. IgE mediated mast cell degranulation in the bronchi release mediators that would cause 
bronchospasm as well as permeability changes in the epithelium. Eosinophilic chemotactic factors cause 
pulmonary and peripheral blood eosinophilia IgG-A.fumigatus, IgA-A.fumigatus   also causes activation of 
complement in the bronchi. It has been demonstrated that there occurs hyper releasability of histamme from 
basophils of ABPA patients (Ricketti et al., 1983). 
Preventive Measures 
In developed countries, where regulations allow higher aflatoxin concentrations in animals, the agricultural 
industries have developed alternative approaches chemoprotection and enterosorption to limit biologically 
effective exposure without the high cost of preventing contamination. Chemoprotection is based on manipulating 
the biochemical processing of aflatoxin to ensure detoxification rather than preventing biological exposure. 
Enterosorption is based on the approach of adding a binding agent to food to prevent the absorption of the toxin 
while the food is in the digestive tract; the combined toxin-sorbent is then excreted in the feces. This approach has 
been used extensively and with great success in the animal feeding industry.  (Williams et al., 2004). 
It has been shown that HEPA filtration can reduce or even eliminate Aspergillus spores from the air (Comet 
et al., 1999). Caring for high-risk patients in rooms supplied with HEPA-filtered air has helped to prevent the 
acquisition of this infection within the hospital (Oren et al., 2001), provided certain technical requirements are met. 
Components of a protected hospital environment should include a well-sealed room, HEPA filtration of incoming 
air, directed (or laminar) airflow within the room, positive room air pressure relative to the corridor, and high rates 
of room air exchange (Center for Disease Control and Prevention, 1997) 
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CRYPTOCOCCOSIS 
Cryptococcosis is a rare fungal infection produced by inhalation of encapsulated yeast called Cryptococcus 
neoformans.   C. neoformans can be found worldwide in soil, pigeon/bird, cat, dog, fox, monkey, cattle, horse, 
goat, and many other mammals’ feces (www.doctorfungus.org, 2008). Recently, a differentiation has been made 
between two species, Cryptococcus gattii (C.gattii) and C. neoformans. This differentiation was made on the basis 
of genetic variation and a lack of evidence for genetic recombination between both gene types (Duncan et al., 
2006a, b). These genetic differences are consistent with differences in habitat, geographical distribution and, most 
importantly, in pathogenicity and the effectiveness of the response of the host immune system. C.neoformans 
infects predominantly immune compromised hosts, while C. gattii has not been associated with a suppressed 
immune system (Duncan et al.,2006a,b) and  is mostly found on eucalyptus trees and in the soil (Traynor and 
Huffnagle, 2001; Duncan et al.,2006a). 
The primary route of entry for Cryptococcus is via the lungs, where the fungus may establish a primary 
infection. If the initial pulmonary infection is not controlled, the fungus can disseminate to other organs and the 
central nervous system, resulting in fatal cryptococcal meningoencephalitis (Traynor and Huffnagle, 2001; Aguirre 
et al., 2004; Chen et al., 2007). 
Human disseminated cryptococcosis has two unusual features that distinguish it from other disseminated 
fungal infections. First, patients have cryptococcal polysaccharide antigen in their body fluids, and detection of 
this is useful in diagnosis of the disease. Second, there is a limited inflammatory response in tissues harbouring C. 
neoformans. One could interpret these findings to mean that individuals with the highest levels of cryptococcal 
polysaccharide in their body fluids simply had higher number of organisms in their tissues and therefore were the 
most likely not to respond to antifungal therapy. Another interpretation could be that the cryptococcal 
polysaccharide had an adverse effect on host defence mechanisms, thus allowing a progressive disease, concluding 
that cryptococcal polysaccharide in the bloodstream exacerbates disease (Clemons et al., 2000). 
Clinical cryptococcosis has been reported worldwide in many animal species. It is the most common systemic 
fungal infection in cats and is often described in dogs (Duncan et al., 2006b).  In cats, C. neoformans is most 
commonly isolated from immunosuppressed individuals, whereas C. gattii is considered as primary pathogen 
because it infects immune competent hosts, even in areas where the organism is endemic (Duncan et al., 2006a). 
In other animal species, cryptococcosis can appear to be related to immune depression, although not always. Then, 
have been described outbreaks of ovine and caprine cryptococcosis with respiratory signs, and without immune 
depression situation detected in those animals (Garcia and Blanco, 2000). In these cases, respiratory symptoms 
associated with cachexia were the predominant clinical picture; liver and brain involvement was also documented 
(Baro et al., 1998). 
Cryptococcosis may occur in horses as a disseminated cryptococcal infection with osteomylitis of both the 
axial and appendicular skeleton produced by C.gattii. The administration of corticoids led to clinical deterioration 
due to immune modulating effects. Administration of systemic corticoids occurred after lesions had appeared; 
however, the horse deteriorated significantly after corticosteroid treatment (Lenard et al., 2007). 
Etiology 
Cryptococcus spps. are fungi in the Division Basidiomycota. Although there are more than 30 species of 
Cryptococcus, only two organisms – C. neoformans and C. gattii (previously C. neoformans var. gattii) - 
commonly affect humans and animals. Other species including C. laurentii, C. albidus, C. uzbekistanensis, C. 
adeliensis, C. curvatus, C. magnus, C. humicolus, C. luteolus, C. macerans, C. flavescens and C. uniguttulatus 
have been found in clinical cases; however, this is rare. Of the latter group of organisms, C. laurentii and C. albidus 
have been described most often in people (The Center for Food Security and Public Health, 2013). 
Host risk factors 
C. neoformansis also an opportunistic pathogen, which can cause cryptococcosis in patients with  
HIV infection and HIV-negative patients with immunological conditions predisposing to this fungal infection, 
such as a history of systemic corticosteroid therapy, immunosuppressive treatments, organ transplant, chronic 
organ failure (liver, lung, and kidney), malignancy,  rheumatic diseases, systemic lupus erythematosus and diabetes 
mellitus (Casadevall et al., 2008).  
Pathogenesis 
Virulence Factors 
C. gattii and C. neoformans share many attributes that increase their ability to invade and survive in a host organism 
(Ellerbroek et al., 2004). The main virulence factors identified in C. gattii to date include an outer polysaccharide 
capsule, melanin, mannitol, extracellular proteinase, products of the laccase pathway, superoxide dismutase, 
phospholipases, urease, and the STE12  transcription factor (a homologue of Saccharomyces cerevisiae STE12) 
that is present only in the  mating type(Chang et al., 2000). Other properties of C. gattii contribute to its infectivity 
such as its ability to grow at physiological temperature (Sorrel, 2001) its tolerance of low pH and elevated salt 
levels (Kidd et al., 2007), and its ability to switch capsular phenotype (Jian et al., 2006). 
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Host defenses  
Clearance of Cryptococcus infection requires the development of a Th1-type CMI and the subsequent pulmonary 
recruitment and activation of leukocytes. The leukocytic infiltrate in response to cryptococcal infection includes a 
mix of myeloid and lymphoid cells, all of which are capable of inhibiting the growth of, or killing, the organism 
in vitro (Romani, 2004). 
Neutrophils and macrophages are the two phagocytic cells in the natural host defence that are most likely to 
be responsible for clearing the cryptococcal cells from the tissues. There was very little inflammatory response, 
i.e. influx of neutrophils, lymphocytes and macrophages, into infected host tissues (Clemons et al., 2000). 
In this Th1-CMI, IFN-g, TNF-a, IL-2, IL-12, IL-15, IL-18, monocyte chemotactic protein-1, macrophage 
inflammatory protein-1a and nitric oxide have been shown to have important roles in murine models. GM-CSF 
plays a complex role in the development of anticryptococcal immunity in the lungs: it is required for early 
recruitment of leukocytes into the lung, movement of recruited leukocytes into the alveolar space and the formation 
of inflammatory foci in the lungs (Chen et al., 2007). 
The Th2 cytokines IL-4 and IL-5 were not secreted at significantly higher levels in Cryptococcus-infected 
brains of immune mice compared to control mice (Uicker et al., 2005). CD4+ T-cells are critical for the control of 
Cryptococcus. An antigen-specific CD4+ T cell response occurs when the T cell receptor recognizes processed 
antigen fragments presented by MHC Class II. Then CD4+ T cells secrete cytokines and proliferate (Kwon-Chung 
et al., 2000). Nevertheless, in the lung, both CD4+ andCD8+ T cells are required to clear the cryptococcal infection. 
If yeasts escape and colonize the brain, rapid proliferation leads to serious central nervous system disease. Work 
with severe T cell and B cell-deficient combined immune deficient mice and wild-type controls has demonstrated 
a CD4+ T cell-mediated resistance to cryptococcal organisms that colonize the brain. Depletion of CD8+ T cells 
had no detectable effect on T cell-mediated resistance in brain in vivo. In contrast, CD8+ T cells play a well-
defined and important role in containment of pulmonary infection (Aguirre et al., 2004). 
Preventive measures 
There is no vaccine available for cryptococcosis; thus, prevention through environmental condition control is vital.  
Reduction of aerosolization of the C. neoformans is key and should be done wetting or chemically disinfecting a 
region, then removing large accumulations of bird/animal droppings.  Corticosteroid medications usage should be 
minimized to prevent cryptococcosis due to their tendency of exacerbating compromised patients conditions 
(http://www.aidsmap.com/en/news; McCarthy, 2006). 
 
FUSARIOSIS 
Fusarium spp.are important infectious filamentous fungi, second only to Aspergillus spp. These fungi are 
ubiquitous in the environment and are found in the soil and air. Interestingly, Fusarium spp. are primarily known 
as plant pathogens but can also infect humans and animals, causing superficial, locally invasive, and disseminated 
disease.(Nucci and Anaissie, 2007). Infection is mainly through inhalation of airborne conidia or via breaks in the 
skin due to trauma and/or burns. Fusarium spp. also produces toxins that can cause food poisoning through the 
consumption of toxin-contaminated food (Dignani & Anaissie, 2004). 
In humans, Fusarium species cause a broad spectrum of infections, including superficial (such as keratitis 
and onychomycosis), locally invasive, or disseminated infections, with the last occurring almost exclusively in 
severely immunocompromised patients (Nucci & Anaissie, 2002). Fusarium species may also cause allergic 
diseases (sinusitis) in immunocompetent individuals (Wickern, 1993) and mycotoxicosis in humans and animals 
following ingestion of food contaminated by toxin-producing Fusarium spp. (Nelson et al., 1994) 
Etiology 
More than 100 species of Fusarium have been identified, but only a few cause infections in humans (Alastruey et 
al., 2008). Fusarium solani (F.solani) is the most frequent cause of invasive disease (in approximately half of all 
cases), followed by F. oxysporum, F. moniliforme (previously F. verticillioides), and F. proliferatum (Torres et 
al., 2011). Other species that rarely cause infections in humans include F. dimerum, F. chlamidosporum, F. 
sacchari, F. antophilum and others. Fusarial keratitis is most commonly caused by F. solani (Doczi et al., 2004), 
whereas fusarial onychomycosis is most commonly caused by F. oxysporum( Brilhante et al., 2005; Godoy et al., 
2004; Ninet et al., 2005). 
Host risk factors 
Neutropenia is one of the most important risk factors for acquiring fusariosis. Patients undergoing Heamtopoetic 
Stem Cell Transplantation(HSCT) or solid organ transplantation, those with hematological malignancies or 
acquired immune deficiency syndrome (AIDS) and those taking pharmacological immunosuppressant therapies 
are at high risk for fusariosis.(Nucci et al., 2004 & Enoch et al., 2006). 
Pathogenesis 
Virulence Factors 
Fusarium species possess several virulence factors, including the ability to produce mycotoxins, including 
trichothecenes, which suppress hum oral and cellular immunity and may also cause tissue breakdown. In addition, 
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Fusarium species have the ability to adhere to prosthetic material and to produce proteases and collagenases 
(Nelson, 1994).   
Host Defenses 
The innate immunity plays a major role in the defense against mold infections (Shoham& Levitz, 2005). 
Macrophages and neutrophils damage fusarial hyphae, and their effect is primed by gamma interferon, granulocyte 
colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) (Gaviria et al., 
1999), and interleukin-15 (Winn et al., 2005). The importance of T-cell defenses against Fusarium is illustrated 
by the occurrence of disseminated fusariosis in non-neutropenic HSCT recipients (Nucci et al., 2004). These 
patients have severe T-cell immunodeficiency caused by multiple therapies for their underlying disease and for 
graft-versus-host disease (GvHD). Further supporting the importance of T-cell immunity and phagocytes is the 
major impact of corticosteroid therapy on the outcome of fusariosis, as shown by the much higher death rate among 
recipients of such therapy than among patients who were not receiving corticosteroids (Nucci et al., 2003). 
Preventive measures 
General preventive measures that should be employed in patients at significant risk of invasive fusariosis, such as 
patients with hematologic malignancies undergoing induction chemotherapy or hematopoietic cell transplantation, 
include: Avoidance of activities associated with skin breakdown, avoidance of contact of areas of skin breakdown 
with tap water., Careful examination for and treatment of onychomycosis and paronychia and surgical debridement 
of infected wounds prior to commencing anti-cancer therapies, delaying severely immunosuppressive therapies 
until areas of skin breakdown are healed, when possible. (Nucci & Anaissie, 2007; Nucci & Anaissie, 2002). 
Following appropriate air and water precautions during periods at risk. These include use of a high efficiency 
particulate air filter and positive pressure isolation rooms, avoiding contact with reservoirs of Fusarium spp, such 
as tap water, and having showers cleaned thoroughly prior to use by high-risk patients(Anaissie et al.,2001; 
Anaissie et al., 2002 ). 
 
PNEUMOCYTIS 
Pneumocystis carinii (P.carinii) is an opportunistic and widespread fungus found in the lungs of humans and other 
mammals. It can be the cause of severe pneumonia, especially in humans suffering from AIDS (Cailliez et al., 
1991). In the veterinary literature P. carinii pneumonia (PCP) has been reported in foals1,(Tanaka et al., 1994) 
(especially Arabian foals with inherited severe combined immunodeficiency, in pigs,(Kondo et al., 1993) and in 
domestic goats. Only a few cases of P. carinii pneumonia have been reported in dogs, and most commonly among 
young animals (Furuta et al., 1994). P. carinii was considered as a group of heterogeneous populations, genetically 
isolated from each other, that have undergone a prolonged process of genetic and functional adaptation to each 
mammalian species (Dei-Cas, 2000). 
Further genetic analysis has shown that Pneumocystis isolated from different species has significant 
differences in gene sequence and chromosomes. This has prompted nomenclature changes and P. carinii is now 
reserved for the rat pathogen, P.carinii f.sp. muris for the murine pathogen, and P. jiroveci for the human pathogen 
(Steele et al., 2005). It may be that this situation will be repeated in different animal species, like the description 
of the genetically different P. canis in dog (English et al., 2001). Pneumocystis pneumonia is a well-recognized 
major opportunistic infection in HIV-positive individuals, and is growing in importance in HIV-negative patients 
undergoing immunosuppressive treatment for malignancy, connective tissue disease or organ transplantation. 
In the veterinary field, Pneumocystis has been described as producing pneumonia in dogs, causing serious 
pulmonary alterations. Pneumocystis is important in horses, where treatment with immunosuppressive drugs, like 
corticoids, is a relatively frequent practice in animals. 
Dedicated to sport, originating a pneumonic process with bronchoneumonic diffuse image. In pigs, this 
fungus gives rise to pneumonic processes, affecting animals 7–11 weeks old, with lung damage that includes a 
decrease of the size of the pulmonary septa with infiltration of mononuclear cells and appearance of exudates in 
the alveoli. This focal pneumonia evolves toward a diffuse pneumonia, very similar to what happens with this 
disease in children (Cavallini et al., 2007). Pneumocystis infects hosts by a respiratory route, and animal-to-animal 
airborne transmission has been clearly established (Dumoulin et al., 2000). In humans, the persistence of 
Pneumocystis in the lung is a limited-time phenomenon inversely related to immunological improvement. A 
normal immune response completely eradicates Pneumocystis from the host. However, immunocompetent hosts 
can be parasitized transiently by Pneumocystis: increased titres of Pneumocystis antibodies were detected in 
hospital staff in close contact with Pneumocystis pneumonia patients, and immunocompetent experimental hosts 
were parasitized transiently by Pneumocystis after close contact with hosts developing pneumonia by this fungus 
(Dei-Cas, 2000). 
Etiology 
Pneumocystis organisms were first reported and named P.carinii in the beginning of last century after recognition 
that pneumocystis organisms in different mammals are different, in1994 an interim trinomial name change was 
adopted with the name P. carinii f.sp hominis for pneumocystis infecting humans and P.carinii f.sp. carinii for 
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one of the two species infecting rats (The Pneumocystis Workshop, 1994). Finally, in 2002, by the recognition of 
its genetic and functional distinctness, human pneumocystis organism was renamed Pneumocystis jiroveci, in 
honour of Otto Jirovec, who is credited for describing the microbe in humans (Frenkel, 1999; Stringer et al., 2002). 
Host risk factors 
Although not fully characterized, the known risk factors for P.jirovecii infection include impaired immunity 
because of HIV infection, hematologic malignancies, and connective tissue disorders (Roblot et al., 2002). 
Pathogenesis 
Host defense 
A host defense against Pneumocystis is indistinguishable from that observed for other medically important fungal 
pathogens of the lung (Steele et al., 2005). As with fungal pathogens such as A. fumigatus, C.neoformans and 
Histoplasma capsulatum(H. capsulatum), alveolar macrophages are an essential component of the immune 
response against Pneumocystis and are ultimately responsible for clearing this fungus from the lungs ( He et 
al.,2003; Steele et al., 2005). CD4+ T cells are absolutely critical for resolution of Pneumocystis, having an 
essential role in the recruitment and activation of effector cells against the organism. CD8+ T cells by themselves 
do not aid clearance of Pneumocystis from the lungs (Dei-Cas, 2000; Traynor & Huffnagle, 2001) 
IFN-ᵞ is not absolutely required for clearing Pneumocystis from the lungs but is required for modulating the 
inflammation (Dei-Cas, 2000). B cells and/or Pneumocystis-specific antibody are important for clearance of 
Pneumocystis from the lungs. Antibodies against Pneumocystis are reported to be readily detectable in the early 
years of life, at ages similar to that reported for other pathogenic fungi such as C. albicans and C. neoformans 
(Goldman et al., 2001; Steele et al., 2005), and most data suggest that the organism is widely encountered in nature 
and that antibody production is part of the natural host response, predominantly of the IgG class, but also IgM. In 
this sense, many ELISA-based assays have been developed and employ a wide variety of Pneumocystis 
preparations and antigens to detect the presence of Pneumocystis-specific antibodies (Steele et al., 2005). 
Preventive Measures 
Adults and adolescents who have HIV infection (including pregnant women and those on HAART) should receive 
Chemoprophylaxis against PCP if they have a CD4+ T-lymphocyte count of less than 200/μL  or a history of or 
pharyngeal candidiasis (Phair et al., 1990). Persons who have a CD4+ T-lymphocyte percentage of less than 14% 
or history of an acquired immunodeficiency syndrome (AIDS)-defining illness but do not otherwise qualify should 
be considered or prophylaxis  (Kaplan et al., 1998). When monitoring the CD4+ T-lymphocyte count at least every 
3 months is not possible, initiation of chemoprophylaxis at a CD4+ T-lymphocyte count of greater than 200 but 
less than 250 cells/μL also should be considered (CDC, 1989). 
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